Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Bivalent IAP antagonists, but not monovalent IAP antagonists, inhibit TNF-mediated NF-κB signaling by degrading TRAF2-associated cIAP1 in cancer cells.

Mitsuuchi Y, Benetatos CA, Deng Y, Haimowitz T, Beck SC, Arnone MR, Kapoor GS, Seipel ME, Chunduru SK, McKinlay MA, Begley CG, Condon SM.

Cell Death Discov. 2017 Jan 16;3:16046. doi: 10.1038/cddiscovery.2016.46. eCollection 2017.

2.

Combination of IAP antagonist and IFNγ activates novel caspase-10- and RIPK1-dependent cell death pathways.

Tanzer MC, Khan N, Rickard JA, Etemadi N, Lalaoui N, Spall SK, Hildebrand JM, Segal D, Miasari M, Chau D, Wong WL, McKinlay M, Chunduru SK, Benetatos CA, Condon SM, Vince JE, Herold MJ, Silke J.

Cell Death Differ. 2017 Mar;24(3):481-491. doi: 10.1038/cdd.2016.147. Epub 2017 Jan 20.

3.

Negative feedback regulation of NF-κB-inducing kinase is proteasome-dependent but does not require cellular inhibitors of apoptosis.

Gray CM, McCorkell KA, Chunduru SK, McKinlay MA, May MJ.

Biochem Biophys Res Commun. 2014 Jul 18;450(1):341-6. doi: 10.1016/j.bbrc.2014.05.122. Epub 2014 Jun 2.

4.

Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies.

Condon SM, Mitsuuchi Y, Deng Y, LaPorte MG, Rippin SR, Haimowitz T, Alexander MD, Kumar PT, Hendi MS, Lee YH, Benetatos CA, Yu G, Kapoor GS, Neiman E, Seipel ME, Burns JM, Graham MA, McKinlay MA, Li X, Wang J, Shi Y, Feltham R, Bettjeman B, Cumming MH, Vince JE, Khan N, Silke J, Day CL, Chunduru SK.

J Med Chem. 2014 May 8;57(9):3666-77. doi: 10.1021/jm500176w. Epub 2014 Apr 15.

PMID:
24684347
5.

Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.

Benetatos CA, Mitsuuchi Y, Burns JM, Neiman EM, Condon SM, Yu G, Seipel ME, Kapoor GS, Laporte MG, Rippin SR, Deng Y, Hendi MS, Tirunahari PK, Lee YH, Haimowitz T, Alexander MD, Graham MA, Weng D, Shi Y, McKinlay MA, Chunduru SK.

Mol Cancer Ther. 2014 Apr;13(4):867-79. doi: 10.1158/1535-7163.MCT-13-0798. Epub 2014 Feb 21. Erratum in: Mol Cancer Ther. 2014 Sep;13(9):2246-7. Dosage error in article text.

6.

The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.

Krepler C, Chunduru SK, Halloran MB, He X, Xiao M, Vultur A, Villanueva J, Mitsuuchi Y, Neiman EM, Benetatos C, Nathanson KL, Amaravadi RK, Pehamberger H, McKinlay M, Herlyn M.

Clin Cancer Res. 2013 Apr 1;19(7):1784-94. doi: 10.1158/1078-0432.CCR-12-2518. Epub 2013 Feb 12.

7.

Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-α but not through TRAIL and FasL.

Jinesh G G, Chunduru S, Kamat AM.

J Leukoc Biol. 2012 Jul;92(1):233-44. doi: 10.1189/jlb.1211623. Epub 2012 Apr 18.

8.

The discovery and structure-activity relationships of pyrano[3,4-b]indole-based inhibitors of hepatitis C virus NS5B polymerase.

Jackson RW, LaPorte MG, Herbertz T, Draper TL, Gaboury JA, Rippin SR, Patel R, Chunduru SK, Benetatos CA, Young DC, Burns CJ, Condon SM.

Bioorg Med Chem Lett. 2011 Jun 1;21(11):3227-31. doi: 10.1016/j.bmcl.2011.04.052. Epub 2011 Apr 21.

PMID:
21550237
9.

Smac mimetics activate the E3 ligase activity of cIAP1 protein by promoting RING domain dimerization.

Feltham R, Bettjeman B, Budhidarmo R, Mace PD, Shirley S, Condon SM, Chunduru SK, McKinlay MA, Vaux DL, Silke J, Day CL.

J Biol Chem. 2011 May 13;286(19):17015-28. doi: 10.1074/jbc.M111.222919. Epub 2011 Mar 10.

10.

Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells.

Metwalli AR, Khanbolooki S, Jinesh G, Sundi D, Shah JB, Shrader M, Choi W, Lashinger LM, Chunduru S, McConkey DJ, McKinlay M, Kamat AM.

Cancer Biol Ther. 2010 Nov 1;10(9):885-92. doi: 10.4161/cbt.10.9.13237. Epub 2010 Nov 1.

11.

Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist.

Griffith TS, Kucaba TA, O'Donnell MA, Burns J, Benetatos C, McKinlay MA, Condon S, Chunduru S.

Apoptosis. 2011 Jan;16(1):13-26. doi: 10.1007/s10495-010-0535-3.

PMID:
20734142
12.

The discovery and structure-activity relationships of pyrano[3,4-b]indole based inhibitors of hepatitis C virus NS5B polymerase.

LaPorte MG, Draper TL, Miller LE, Blackledge CW, Leister LK, Amparo E, Hussey AR, Young DC, Chunduru SK, Benetatos CA, Rhodes G, Gopalsamy A, Herbertz T, Burns CJ, Condon SM.

Bioorg Med Chem Lett. 2010 May 1;20(9):2968-73. doi: 10.1016/j.bmcl.2010.03.002. Epub 2010 Mar 6.

PMID:
20347591
13.

The discovery of pyrano[3,4-b]indole-based allosteric inhibitors of HCV NS5B polymerase with in vivo activity.

Laporte MG, Jackson RW, Draper TL, Gaboury JA, Galie K, Herbertz T, Hussey AR, Rippin SR, Benetatos CA, Chunduru SK, Christensen JS, Coburn GA, Rizzo CJ, Rhodes G, O'Connell J, Howe AY, Mansour TS, Collett MS, Pevear DC, Young DC, Gao T, Tyrrell DL, Kneteman NM, Burns CJ, Condon SM.

ChemMedChem. 2008 Oct;3(10):1508-15. doi: 10.1002/cmdc.200800168. No abstract available.

PMID:
18729128
14.

TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha.

Vince JE, Chau D, Callus B, Wong WW, Hawkins CJ, Schneider P, McKinlay M, Benetatos CA, Condon SM, Chunduru SK, Yeoh G, Brink R, Vaux DL, Silke J.

J Cell Biol. 2008 Jul 14;182(1):171-84. doi: 10.1083/jcb.200801010. Epub 2008 Jul 7.

15.

Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.

Howe AY, Cheng H, Johann S, Mullen S, Chunduru SK, Young DC, Bard J, Chopra R, Krishnamurthy G, Mansour T, O'Connell J.

Antimicrob Agents Chemother. 2008 Sep;52(9):3327-38. doi: 10.1128/AAC.00238-08. Epub 2008 Jun 16.

16.

IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis.

Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, Benetatos CA, Chunduru SK, Condon SM, McKinlay M, Brink R, Leverkus M, Tergaonkar V, Schneider P, Callus BA, Koentgen F, Vaux DL, Silke J.

Cell. 2007 Nov 16;131(4):682-93.

17.

Molecular mechanism of a thumb domain hepatitis C virus nonnucleoside RNA-dependent RNA polymerase inhibitor.

Howe AY, Cheng H, Thompson I, Chunduru SK, Herrmann S, O'Connell J, Agarwal A, Chopra R, Del Vecchio AM.

Antimicrob Agents Chemother. 2006 Dec;50(12):4103-13. Epub 2006 Aug 28.

18.

Tetrahydrobenzothiophene inhibitors of hepatitis C virus NS5B polymerase.

Laporte MG, Lessen TA, Leister L, Cebzanov D, Amparo E, Faust C, Ortlip D, Bailey TR, Nitz TJ, Chunduru SK, Young DC, Burns CJ.

Bioorg Med Chem Lett. 2006 Jan 1;16(1):100-3. Epub 2005 Nov 2.

PMID:
16260131
19.

Novel nonnucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase.

Howe AY, Bloom J, Baldick CJ, Benetatos CA, Cheng H, Christensen JS, Chunduru SK, Coburn GA, Feld B, Gopalsamy A, Gorczyca WP, Herrmann S, Johann S, Jiang X, Kimberland ML, Krisnamurthy G, Olson M, Orlowski M, Swanberg S, Thompson I, Thorn M, Del Vecchio A, Young DC, van Zeijl M, Ellingboe JW, Upeslacis J, Collett M, Mansour TS, O'Connell JF.

Antimicrob Agents Chemother. 2004 Dec;48(12):4813-21.

20.

Newly synthesized hepatitis C virus replicon RNA is protected from nuclease activity by a protease-sensitive factor(s).

Yang G, Pevear DC, Collett MS, Chunduru S, Young DC, Benetatos C, Jordan R.

J Virol. 2004 Sep;78(18):10202-5.

21.

Identification of an alternatively spliced RNA for the Ras suppressor RSU-1 in human gliomas.

Chunduru S, Kawami H, Gullick R, Monacci WJ, Dougherty G, Cutler ML.

J Neurooncol. 2002 Dec;60(3):201-11.

PMID:
12510772
22.

Mechanism of action of a pestivirus antiviral compound.

Baginski SG, Pevear DC, Seipel M, Sun SC, Benetatos CA, Chunduru SK, Rice CM, Collett MS.

Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7981-6.

23.

Exploitation of the Vbeta8.2 T cell receptor in protection against experimental autoimmune encephalomyelitis using a live vaccinia virus vector.

Chunduru SK, Sutherland RM, Stewart GA, Doms RW, Paterson Y.

J Immunol. 1996 Jun 15;156(12):4940-5.

PMID:
8648145
24.

In vivo model of adeno-associated virus vector persistence and rescue.

Afione SA, Conrad CK, Kearns WG, Chunduru S, Adams R, Reynolds TC, Guggino WB, Cutting GR, Carter BJ, Flotte TR.

J Virol. 1996 May;70(5):3235-41.

25.

Mutations in the gene for human dihydrofolate reductase: an unlikely cause of clinical relapse in pediatric leukemia after therapy with methotrexate.

Spencer HT, Sorrentino BP, Pui CH, Chunduru SK, Sleep SE, Blakley RL.

Leukemia. 1996 Mar;10(3):439-46.

PMID:
8642859
26.

Methotrexate-resistant variants of human dihydrofolate reductase with substitutions of leucine 22. Kinetics, crystallography, and potential as selectable markers.

Lewis WS, Cody V, Galitsky N, Luft JR, Pangborn W, Chunduru SK, Spencer HT, Appleman JR, Blakley RL.

J Biol Chem. 1995 Mar 10;270(10):5057-64.

27.

Methotrexate-resistant variants of human dihydrofolate reductase. Effects of Phe31 substitutions.

Chunduru SK, Cody V, Luft JR, Pangborn W, Appleman JR, Blakley RL.

J Biol Chem. 1994 Apr 1;269(13):9547-55.

29.

Kinetic investigation of methotrexate resistant human dihydrofolate reductase (hDHFR) mutants at Phe31.

Chunduru SK, Appleman JR, Blakley RL.

Adv Exp Med Biol. 1993;338:507-10. No abstract available.

PMID:
8304168
30.

Mutations of human dihydrofolate reductase causing decreased inhibition by methotrexate.

Blakley RL, Appleman JR, Chunduru SK, Nakano T, Lewis WS, Harris SE.

Adv Exp Med Biol. 1993;338:473-9. No abstract available.

PMID:
8304162
31.
32.

Mechanism of ketol acid reductoisomerase--steady-state analysis and metal ion requirement.

Chunduru SK, Mrachko GT, Calvo KC.

Biochemistry. 1989 Jan 24;28(2):486-93.

PMID:
2653423

Supplemental Content

Loading ...
Support Center